To the full analysis
Zealand Pharma stock: growth
ZEAL.COZealand Pharma reported $1.37B in revenue for fiscal 2025, up 14,598.9% on the prior year, up 92% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
32.3%
per year from 2007 to 2025, per share 22.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2007 | |
|---|---|---|---|
| Revenue | 92.0% | 47.6% | 32.3% |
| Revenue per share | 70.0% | 32.0% | 22.5% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $8.88M | −$8.15M | −$8.89M |
| 2008 | $8.34M | −$5M | −$4.74M |
| 2009 | $3.75M | −$11.86M | −$9.64M |
| 2010 | $12.95M | −$15.51M | −$8.93M |
| 2011 | $21.09M | $1.01M | −$1.97M |
| 2012 | $33.14M | $5.39M | $8.85M |
| 2013 | $974.48K | −$27.24M | −$25.82M |
| 2014 | $22.79M | −$9.63M | −$6.92M |
| 2015 | $27.82M | −$16.89M | −$34.01M |
| 2016 | $34.8M | −$22.81M | $5.68M |
| 2017 | $20.72M | −$40.36M | −$42.39M |
| 2018 | $5.63M | $86.17M | −$68.84M |
| 2019 | $6.13M | −$84.72M | −$64.18M |
| 2020 | $52.37M | −$125.51M | −$105.8M |
| 2021 | $43.37M | −$150.92M | −$182.93M |
| 2022 | $15.41M | −$143.14M | −$141.4M |
| 2023 | $50.81M | −$104.32M | −$66.62M |
| 2024 | $9.29M | −$159.92M | −$139.93M |
| 2025 | $1.37B | $956.84M | $963.3M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = DKK 6.7461)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.